Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

Gema Miñana, Julio Núñez, Antoni Bayés-Genís*, Elena Revuelta-López, César Ríos-Navarro, Eduardo Núñez, Francisco J. Chorro, Maria Pilar López-Lereu, Jose Vicente Monmeneu, Josep Lupón, Juan Sanchis, Vicent Bodí

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)


Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). Methods and results: We prospectively evaluated 40 patients with a first STEMI, LVEF < 50% and treated with primary percutaneous coronary intervention in which PCSK9 was measured 24 h postreperfusion. All patients underwent cardiac magnetic resonance imaging 1 week and 6 months after STEMI. Baseline characteristics were compared across median values of PCSK9. The association between PCSK9 levels and LVEF at 6 months was evaluated by analysis of covariance. The mean age of the sample was 60 ± 12 years and 33 (82.5%) were male patients. The infarct location was anterior in 27 patients (67.5%), and 9 patients (22.5%) were Killip class ≥ II. The mean 1 week and 6 month LVEF were 41 ± 7% and 48 ± 10%, respectively. The mean PCSK9 was 1.93 ± 0.38 U/mL. Testing the association between serum PCSK9 and 6 month LVEF with analysis of covariance revealed an inverse relationship (r = −0.35, P = 0.028). After multivariate adjustment, circulating PCSK9 remained significant and inversely associated with 6 month LVEF (P = 0.002). Conclusions: In patients with a first STEMI with reduced ejection fraction at index admission and treated with primary percutaneous coronary intervention, circulating PCSK9 was associated with lower LVEF at 6 months.

Original languageAmerican English
Pages (from-to)117-122
Number of pages6
JournalESC heart failure
Issue number1
Publication statusPublished - 1 Feb 2020


  • Cardiac magnetic resonance
  • Left ventricular ejection fraction
  • PCSK9
  • ST-segment elevation myocardial infarction


Dive into the research topics of 'Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study'. Together they form a unique fingerprint.

Cite this